Skip to content

Free cash flow at other companies

Pfizer logo
PfizerPFE
$2.18B+23.0%
Opko Health logo
Opko HealthOPK
-$21.14M+44.0%
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
-$44.95M-10.1%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
Viatris logo
ViatrisVTRS
AptarGroup logo
AptarGroupATR

Other financials

Income statement

See full
Revenue$171.2M+0.4%
Gross profit$70.3M-17.5%
Operating income$13.6M-63.5%
Net income$6.4M-74.6%
EPS (diluted)$0.14-72.5%

Balance sheet

See full
Cash & equivalents$170.9M-6.5%
Total debt$686.6M+5.2%
Total equity$445.5M
Total assets$1.6B+1.3%

Cash flow

See full
Operating cash flow$47.8M+36.4%
CapEx$9.5M-11.1%

Valuation

See full
Market cap$926.83M-19.9%
Enterprise value$1.44B-11.4%
P/E11.7×+3.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin47.3%-3.2pp
Operating margin16.2%-10.4pp
Net margin11%-8.4pp
FCF margin18.8%-1.8pp

Returns & leverage

See full
Return on equity14.7%
Debt / equity0.2×
Current ratio3.9×+0.9×

Where this comes from

Calculated from Amphastar Pharmaceuticals’s reported figures.

The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amphastar Pharmaceuticals's free cash flow?
Amphastar Pharmaceuticals (AMPH) reported free cash flow of $38.33M in Q1 2026.
How has Amphastar Pharmaceuticals's free cash flow changed year-over-year?
Amphastar Pharmaceuticals's free cash flow increased by 57.2% year-over-year, from $24.38M to $38.33M.
What is the long-term trend for Amphastar Pharmaceuticals's free cash flow?
Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's free cash flow has grown at a 12.7% compound annual growth rate (CAGR), from $75.19M to $121.23M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.